研究業績
- 1．Dansako H, Ikeda M, Ariumi Y, Togashi Y, Kato N: Hepatitis C virus NS5B triggers an MDA5-mediated innate immune response by producing dsRNA without the replication of viral genomes. FEBS J. Vol 291, 1119-1130, 2024.
- 2．Eltalkhawy YM, Takahashi N, Ariumi Y, Shimizu J, Miyazaki K, Senju S, Suzu S: iPS cell-derived model to study the interaction between tissue macrophage and HIV-1. J. Leukoc Biol Vol. 114, 53-67, 2023.
- 3．Ariumi Y: Hepatitis B virus polymerase restricts LINE-1 retrotransposition. Gene Vol. 850, 146943, 2023.
- 4．Ariumi Y: Host cellular RNA helicases regulate SARS-CoV-2 infection. Journal of Virology, 96:e0000222, 2022.
- 5．Yamamoto N, Nishida N, Yamamoto R, Gojobori T, Shimotohno K, Mizokami M, Ariumi Y: Angiotensin-converting enzyme (ACE) 1 gene polymorphism and phenotypic expression of COVID-19 symptoms. Genes, 12:1572. 2021.
- 6．Yamamoto N, Yamamoto R, Ariumi Y, Mizokami M, Shimotohno K, Yoshikura H: Does genetic predisposition contribute to the exacerbation of COVID-19 symptoms in individuals with comorbidities and explain the huge mortality disparity between the East and the West?
Int. J. Mol. Sci. 22:5000, 2021.
- 7．Yamamoto N*, Ariumi Y* (*Co-first authors), Nishida N, Yamamoto R, Bauer G, Gojobori T, Shimotohno K, Mizokami M. SARS-CoV-2 infection and COVID-19 mortalities strongly correlate with ACE1 I/D genotype. Gene Vol. 758, 144944, 2020.
- 8．M. Ueno, M. Nogawa, R. Siddiqui, K. Watashi, T. Wakita, N. Kato, M. Ikeda, T. Okimura, S. Isaka, T. Oda,Y. Ariumi: Acidic polysaccharides isolated from marine algae inhibit the early step of viral infection. International Journal of Biological Macromolecules, Vol. 124, 282-290, 2019.
- 9．Ariumi Y, K. Kawano, M. Yasuda-Inoue, H. Fukuda, R. Siddiqui, P. Turelli, S. Tateishi: DNA repair protein Rad18 restricts LINE-1 mobility. Scientific Reports, Vol. 8, 15894, 2018
- 10．R. Siddiqui, S. Suzu, M. Ueno, H. Nasser, R. Koba, F. Bhuyan, O. Noyori, M. Yasuda-Inoue, T. Hishiki, S.Sukegawa, E. Miyagi, K. Strebel, S. Matsushita, K. Shimotohno, Y. Ariumi: Apolipoprotein E is an HIV-1- inducible inhibitor of viral production and infectivity in macrophages. PLoS Pathogens, Vol.14,e1007372, 2018.
- 11．K. Kawano, A.J. Doucet, M. Ueno, M. Kuroki, P. Turelli, W. An, G. Cristofari, D. Trono, Y. Ariumi: HIV-1 Vpr and p21Waf1 restrict the LINE-1 mobility. Nucleic Acids Research, Vol. 46, 8454-8470, 2018
- 12．Ariumi Y: Guardian of the Human Genome: Host Defense Mechanisms against LINE-1 Retrotransposition. Frontiers in Chemistry, Vol. 4, 28, 2016
- 13．Ariumi Y: Multiple functions of DDX3 RNA helicase in gene regulation, tumorigenesis, and viral infection. Frontiers in Genetics, Vol. 5, 423, 2014
- 14．M. Yasuda-Inoue, M. Kuroki, Y. Ariumi: DDX3 RNA helicase is required for HIV-1 Tat function. Biochemical and Biophysical Research Communications, Vol. 441, 607-611, 2013
- 15．M. Yasuda-Inoue, M. Kuroki, Y. Ariumi: Distinct DDX DEAD-box RNA helicases cooperate to modulate the HIV-1 Rev function. Biochemical and Biophysical Research Communications, Vol. 434, 803-808, 2013
- 16．Y. Yagita, N. Kuse, K. Kuroki, H. Gatanaga, J. Carlson, T. Chikata, Z. Brumme, H. Murakoshi, T. Akahoshi, N. Pfeifer, S. Mallal, M. John, T. Ose, H. Matsubara, R. Kanda, Y. Fukunaga, K. Honda, Y. Kawashima, Y. Ariumi, S. Oka, K. Maenaka, M. Takiguchi: Distinct HIV-1 escape patterns selected by CTLs with identical epitope specificity. Journal of Virology, Vol. 87, 2253-2263, 2013
- 17．K. Mori, O. Hiraoka, M. Ikeda, Y. Ariumi, A. Hiramoto, Y. Wataya, N. Kato: Adenosine kinase is a key determinant for the anti-HCV activity of ribavirin. Hepatology, Vol. 58, 1236-1244, 2013
- 18．M. Kuroki, Y. Ariumi, M. Hijikata, M. Ikeda, H. Dansako, T. Wakita, K. Shimotohno, N. Kato: PML tumor suppressor protein is required for HCV production. Biochemical and Biophysical Research Communications, Vol. 430, 592-597, 2013
- 19．K. Osugi, H. Suzuki, T. Nomura, Y. Ariumi, H. Shibata, M. Maki: Identification of the P-body component PATL1 as a novel ALG-2-interacting protein by in silico and Far-Western screening of proline-rich proteins. Journal of Biochemistry, Vol. 151, 657-666, 2012
- 20．M. Takeda, M. Ikeda, K. Mori , M. Yano, Y. Ariumi, H. Dansako, T. Wakita, N. Kato: Raloxifene inhibits hepatitis C virus infection and replication. FEBS Open Bio, Vol. 2, 279-283, 2012
- 21．H. Sejima, K. Mori, Y. Ariumi, M. Ikeda, N. Kato: Identification of host genes showing differential expression profiles with cell-based long-term replication of hepatitis C virus RNA. Virus Research, Vol. 167, 74-85, 2012
- 22．M. Takeda, M. Ikeda, Y. Ariumi, T. Wakita, N. Kato: Development of hepatitis C virus production reporter assay systems using two different hepatoma cell lines. Journal of General Virology, Vol. 93, 1422-1431, 2012
- 23．K. Mori, Y. Ueda, Y. Ariumi, H. Dansako, M. Ikeda, N. Kato: Development of a drug assay system with hepatitis C virus genome derived from a patient with acute hepatitis C. Virus Genes, Vol. 44, 374-381, 2012
- 24．Ariumi Y, M. Kuroki, Y. Kushima, K. Osugi, M. Hijikata, M. Maki, M. Ikeda, N. Kato: Hepatitis C virus hijacks P-body and stress granule components around lipid droplets. Journal of Virology, Vol. 85, 6882-6892, 2011
- 25．Ariumi Y, M. Kuroki, M. Maki, M. Ikeda, H. Dansako, T. Wakita, N. Kato: The ESCRT system is required for hepatitis C virus production. PLoS One, Vol. 6, e14517, 2011.
- 26．Y. Ueda, K. Mori, Y. Ariumi, M. Ikeda, N. Kato: Plural assay systems derived from different cell lines and hepatitis C virus strains are required for the objective evaluation of anti-hepatitis C virus reagents. Biochemical and Biophysical Research Communications, Vol. 409:663-668, 2011.
- 27．K. Mori, M. Ikeda, Y. Ariumi, H. Dansako, T. Wakita, N. Kato: Mechanism of action of ribavirin in a novel hepatitis C virus replication cell system. Virus Research, Vol. 151, 61-70, 2011
- 28．M. Ikeda, Y. Kawai, K. Mori, M. Yano, K. Abe, G. Nishimura, H. Dansako, Y. Ariumi, T. Wakita, K. Yamamoto, N. Kato: Anti-ulcer agent teprenone inhibits hepatitis C virus replication. Liver International, Vol. 31, 871-880, 2011
- 29．K. Mori, M. Ikeda, Y. Ariumi, N. Kato: Gene expression profile of Li23, a new human hepatoma cell line that enables robust hepatitis C virus replication: Comparison with HuH-7 and other hepatitc cell lines. Hepatology Research, Vol. 40, 1248-1253, 2010
- 30．F. Ikeda, H. Dansako, G. Nishimura, K. Mori, Y. Kawai, Y. Ariumi, Y. Miyake, A. Takaki, K. Nouso, Y. Iwasaki, M. Ikeda, N. Kato, K. Yamamoto: Amino acid substitutions of hepatitis C virus core protein are not associated with intracellular antiviral response to interferon- in vitro. Liver International, Vol. 30, 1324-1331, 2010
- 31．K. Abe, M. Ikeda, Y. Ariumi, H. Dansako, T. Wakita, N. Kato: HCV genotype 1b chimeric replicon with NS5B of JFH-1 exhibited resistance to cyclosporine A. Archives of Virology, Vol. 154, 1671-1677, 2009
- 32．N. Kato, K. Mori, K. Abe, H. Dansako, M. Kuroki, Y. Ariumi, T. Wakita, M. Ikeda: Efficient replication systems for hepatitis C virus using a new human hepatoma cell line. Virus Research, Vol. 146, 41-50, 2009
- 33．M. Yano, M. Ikeda, K. Abe, Y. Kawai, M. Kuroki, K. Mori, H. Dansako, Y. Ariumi, S. Ohkoshi, Y. Aoyagi, N. Kato: Oxidative stress induces anti-hapatitis C virus status via the activation of extracellular signal-regulated kinase. Hepatology, Vol. 50, 678-688, 2009
- 34．Y. Kawai, M. Ikeda, K. Abe, M. Yano, Y. Ariumi, H. Dansako, K. Yamamoto, N. Kato: Development of a hepatitis C virus relapse model using genome-length hepatitis C virus ribonucleic acid-harboring cells possessing the interferon-alpha-resistance phenotype. Hepatology Research, Vol. 39, 898-909, 2009
- 35．G. Nishimura, M. Ikeda, K. Mori, T. Nakazawa, Y. Ariumi, H. Dansako, N. Kato: Replicons from genotype 1b HCV-positive sera exhibit diverse sensitivities to anti-HCV reagents. Antiviral Research, Vol. 82, 42-50, 2009
- 36．H. Dansako, M. Ikeda, Y. Ariumi, T. Wakita, N. Kato: Double-stranded RNA-induced interferon-beta and inflammatory cytokine production modulated by hepatitis C virus serine protease derived from patients with hepatic diseases. Archives of Virology, Vol.154, 801-810, 2009
- 37．M. Ikeda, M, K. Mori, Y. Ariumi, H. Dansako, N. Kato: Oncostatin M synergistically inhibits HCV RNA replication in combination with interferon-alpha. FEBS Letters, Vol. 583, 1434-1438, 2009
- 38．M. Kuroki, Y. Ariumi, M. Ikeda, H. Dansako, T. Wakita, N. Kato: Arsenic trioxide inhibits hepatitis C virus RNA replication through modulation of the glutathione redox system and oxidative stress. Journal of Virology, Vol. 83, 2338-2348, 2009
- 39．N. Kato, K, Abe, K. Mori, Y. Ariumi, H. Dansako, M. Ikeda: Genetic variability and diversity of intracellular genome-length hepatitis C virus RNA in long-term cell culture. Archives of Virology, Vol. 154, 77-85, 2009
- 40．Ariumi Y, M. Kuroki, K. Abe, H. Dansako, M. Ikeda, T. Wakita, N. Kato: The DNA damage sensors ataxia-telangiectasia mutated kinase and checkpoint kinase 2 are required for hepatitis C virus RNA replication. Journal of Virology, Vol. 82, 9639-9646, 2008
- 41．H. Dansako, M. Ikeda, K. Abe, K. Mori, K. Takemoto, Y. Ariumi, N. Kato: A new living cell-based assay system for monitoring genome-length hepatitis C virus RNA replication. Virus Research, Vol. 137, 72-79, 2008
- 42．K. Mori, K. Abe, H. Dansako, Y. Ariumi, M. Ikeda, N. Kato: New efficient replication system with hepatitis C virus genome derived from a patient with acute hepatitis C. Biochemical and Biophysical Research Communications, Vol. 371, 104-109, 2008
- 43．Ariumi Y, M. Kuroki, K. Abe, H. Dansako, M. Ikeda, T. Wakita, N. Kato: DDX3 DEAD box RNA helicase is required for hepatitis C virus (HCV) RNA replication. Journal of Virology, Vol. 81, 13922-13926, 2007
- 44．K. Abe, M. Ikeda, Y. Ariumi, H. Dansako, N. Kato: Serum-free cell culture system supplemented with lipid-rich albumin for hepatitis C virus (strain O of genotype 1b) replication. Virus Research, Vol. 125, 162-168, 2007
- 45．Ariumi Y, F. Serhan, P. Turelli, A. Telenti, D. Trono: The integrase interactor 1 (INI1) proteins facilitate Tat-mediated human immunodeficiency virus type 1 transcription. Retrovirology, Vol. 3, 47, 2006
- 46．Ariumi Y, D. Trono: Ataxia-telangiectasia-mutated (ATM) protein can enhance human immunodeficiency virus type 1 replication by stimulating Rev function. Journal of Virology, Vol. 80, 2445-2452, 2006
- 47．A. Kaida, Y. Ariumi Y, K. Baba. M. Matsubae, T. Takao, K. Shimotohno: Identification of a novel p300-specific associating protein, phosphoribosyl pyrophosphate synthetase subunit 1 (PRS1). Biochemical Journal, Vol. 391, 239-247, 2005
- 48．Ariumi Y, P. Turelli, M. Masutani, D. Trono: The DNA damage sensors ATM, ATR, DNA-PKcs and PARP-1 are dispensable for human immunodeficiency virus type 1 integration. Journal of Virology, Vol. 79, 2973-8, 2005
- 49．S. Kawata, Y. Ariumi, K. Shimotohno: p21Waf1/Cip1/Sdi1 functions to prevent apoptosis as well as stimulate growth in cells transformed or immortalized by human T-cell leukemia virus type 1-encoded Tax. Journal of Virology, Vol. 77, 7291-7299, 2003
- 50．Ariumi Y, T. Ego, A. Kaida, M. Matsumoto, P.P. Pandolfi, K. Shimotohno: Distinct nuclear body components, PML and SMRT, regulate the trans-acting function of HTLV-1 Tax oncoprotein. Oncogene, Vol. 22, 1611-1619, 2003
- 51．T. Ego, Y. Ariumi, K. Shimotohno: The interaction of HTLV-1 Tax with HDAC1 negatively regulates the viral gene expression. Oncogene, Vol. 21, 7241-7246, 2002
- 52．Ariumi Y, A. Kaida, M. Hatanaka, K. Shimotohno: Functional cross-talk of HIV-1 Tat with p53 through its C-terminal domain. Biochemical and Biophysical Research Communications, Vol. 287, 556-561, 2001.
- 53．Ariumi Y, A. Kaida, J. Y. Lin, M. Hirota, O. Masui, S. Yamaoka, Y. Taya, K. Shimotohno: HTLV-1 tax oncoprotein represses the p53-mediated trans-activation function through coactivator CBP sequestration. Oncogene, Vol. 19, 1491-1499, 2000
- 54．A. Kaida, Y. Ariumi, Y. Ueda, J. Y. Lin, M. Hijikata, S. Ikawa, K. Shimotohno: Functional impairment of p73 and p51, the p53-related proteins, by the human T-cell leukemia virus type 1 Tax oncoprotein. Oncogene, 19, 827-830, 2000
- 55．Ariumi Y, M. Masutani, T. D. Copeland, T. Mimori, T. Sugimura, K. Shimotohno, K. Ueda, M. Hatanaka, M. Noda: Suppression of the poly(ADP-ribose) polymerase activity by DNA-dependent protein kinase in vitro. Oncogene: 18, 4616-4625, 1999
- 56．Ariumi, Y., K. Ueda, M. Masutani, T. D. Copeland, M. Noda, M. Hatanaka, K. Shimotohno: In vivo phosphorylation of poly(ADP-ribose) polymerase is independent of its activation. FEBS Letters, 436: 288-292, 1998
- 57．Ariumi Y, K. Shimotohno, M. Noda, M. Hatanaka: Characterization of the internal promoter of human T-cell leukemia virus type I. FEBS Letters, 423, 25-30, 1998
- 58．Ariumi Y, Copeland TD, Nosaka T, Hatanaka M: HIRF: a novel nuclear factor that binds to the human T-cell leukemia virus type I internal regulatory element (HIRE). Leukemia 11 Suppl 3: 29-31, 1997.
- 59．T. Nosaka, Y. Ariumi, M. Sakurai, R. Takeuchi, M. Hatanaka: Novel internal promoter/enhancer of HTLV-I for Tax expression. Nucleic Acids Research, Vol. 21, 5124-5129, 1993,
- 60．T. Nosaka, T. Takamatsu, Y. Miyazaki, K. Sano, A. Sato, S. Kubota, M. Sakurai, Y. Ariumi, M. Nakai, S. Fujita, M. Hatanaka: Cytotoxic activity of rev protein of human immunodeficiency virus type 1 by nucleolar dysfunction. Experimental Cell Research, 209: 89-102, 1993
日本語解説
1．有海康雄, マクロファージで誘導される新規HIV-1感染抑制因子ApoE. 医学のあゆみ TOPICS 271,1308-1309, 2019
2．有海康雄，加藤宣之．HCVによる肝発癌機構．日本臨床 増刊号 新時代のウイルス性肝炎学 —基礎・臨床研究の進歩 日本臨床社, 69: 増刊4号, 64-68, 2011
3．有海康雄，加藤宣之．DNA損傷センサーATMキナーゼとChk2はC型肝炎ウイルスのRNA複製に必要である．岡山医学会雑誌122: 9-16, 2010
4．有海康雄．C型肝炎ウイルスの感染性ウイルス粒子形成のメカニズム．生物学に関する試験論叢25: 16-31, 2010
5．有海康雄，加藤宣之．肝癌HCVによる発癌メカニズム 慢性感染から肝癌に至るパスウェイ．日本臨床 67: 増刊3: 138-142, 2009
6．有海康雄，加藤宣之．ウイルス感染と発癌．臨床検査53: 29-35, 2009
7．有海康雄，下遠野邦忠．アセチル化によるp53の機能制御．解明が進むp53の新機能，実験医学（羊土社）18: 2219-2224, 2000
著書
1．有海康雄，生命科学のためのウイルス学 感染と宿主応答のしくみ 医療への応用，南江堂，23-43，2015